Search Results for "Cobra Biologics Ma"
Original Source: 2nd Annual Disruptive Innovations to Advance Clinical Trials for Pharma, Biologics & Devices
Translating Disruptive Innovation into Organizational Change
Matching Channels
The iBioLaunch™ platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins. The plants are easily and...
Biosimilars - news, reports, views and blogs
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusi...
Baxter is one of the 30 largest pharmaceutical companies in the world with annual sales of $7.8 billion. With a foot in both the pharmaceutical industry and medical devices, Baxter Healthcare has...
With annual sales reaching $15 billion in 2010, Medtronic is the 4th largest medical devices company in the world (based on annual sales). The device portfolio of Medtronic is broad; covering card...
Technical Background Tumor necrosis factor (TNF) is a substance made by your body's immune system. People with inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic a...
Matching News
Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody (News)
Cobra Biologics Ltd, the international clinical and commercial contract manufacturer of biologics and pharmaceuticals and Algeta ASA, a company focused on the development of novel targeted cancer ...
11 June 2013: Cobra Biologics Ltd, the International clinical and commercial manufacturer of biologics and pharmaceuticals and Novolytics, a biotechnology company developing anti-infective products, ....
Cobra Biologics in manufacturing agreement for Recopharma
Biologics and pharmaceuticals manufacturer, Cobra Biologics Ltd, and Recopharma, a biotechnology company developing ophthalmic products, have formed an agreement in which Cobra Biologics will apply it...
Cobra Biologics talks recent fill finish acquisition and future growth plans
CMO Cobra Biologics says North America is an obvious place to look at for a facility acquisition.
A New Non-Executive Director Joins Cobra's Board to Support Expansion Plans (News)
23 October 2012: Keele, UK - Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals, announces the appointment of a new non-executive director to ...
Cobra Biologics, Vaccibody in DNA Vax-Pact
Cobra to supply clinical trials materials
Cobra Biologics, Novolytics Achieve Bacterial Breakthrough
Cobra increases yields for Staphylococcus aureus products
Cobra Biologics, Vaccibody to manufacture DNA vaccine
Cobra Biologics, an international clinical and commercial manufacturer of biologics and pharmaceuticals, and Vaccibody, a biotechnology company developing the next generation of vaccines against cance...
Matching PubMed Articles
Elimination of thermodynamically infeasible loops in steady-state metabolic models.
The constraint-based reconstruction and analysis (COBRA) framework has been widely used to study steady-state flux solutions in genome-scale metabolic networks. One shortcoming of current COBRA method...
OBJECTIVE: To investigate the influence of biologics on mortality and risk factors for death in rheumatoid arthritis (RA) patients. METHODS: RA patients treated with at least one dose of biologics in...
Clinical pharmacology considerations in biologics development.
Biologics, including monoclonal antibodies (mAbs) and other therapeutic proteins such as cytokines and growth hormones, have unique characteristics compared to small molecules. This paper starts from...
Challenges and approaches for the development of safer immunomodulatory biologics.
Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer an...
Pandemic outbreaks of influenza are caused by the emergence of a pathogenic and transmissible virus to which the human population is immunologically naïve. Recent outbreaks of highly pathogenic avian...
